Physician profile
Ali Hamraz
NPI 1083901961
$10,894.55
in general payments reported to CMS, 2019-2025
44 companies · $2,617 in 2025
The $2,617 reported for 2025 was more than what 81% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $497 · 2020: $246 · 2021: $128 · 2022: $2,403 · 2023: $2,563 · 2024: $2,440 · 2025: $2,617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,619.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,736.49 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,278.77 | 2020-2025 | Evenity, Prolia, Tepezza |
| Bayer Healthcare Pharmaceuticals INC. | $978.32 | 2022-2025 | |
| Radius Health, INC. | $826.91 | 2022-2025 | Tymlos |
| Lilly USA, LLC | $707.48 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $634.13 | 2020-2025 | Jardiance |
| Corcept Therapeutics | $607.41 | 2019-2024 | Korlym |
| Mannkind Corporation | $378.14 | 2021-2025 | Afrezza |
| Antares Pharma, INC. | $338.90 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Sanofi-Aventis U.S. LLC | $297.31 | 2022-2025 | |
| Beta Bionics, INC. | $267.66 | 2024 | Ilet Bionic Pancreas |
| Dexcom, INC. | $262.25 | 2022-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Abbvie INC. | $206.87 | 2022-2025 | |
| Recordati_rare_diseases_inc. | $183.88 | 2022-2025 | Isturisa, Signifor Lar |
| Medtronic, INC. | $168.66 | 2022-2025 | Minimed 780g |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $163.44 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Alexion Pharmaceuticals, INC. | $150.90 | 2024-2025 | Strensiq |
| Verity Pharmaceuticals INC. | $132.00 | 2024 | Tlando |
| Halozyme INC | $123.93 | 2023 | |
| Ibsa Pharma INC. | $116.38 | 2023 | Tirosint |
| Abbott Laboratories | $114.78 | 2022-2023 | Freestyle Libre 3 |
| Madrigal Pharmaceuticals | $114.56 | 2025 | Rezdiffra |
| Astrazeneca Pharmaceuticals LP | $114.23 | 2019 | |
| Tandem Diabetes Care, INC. | $112.65 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Kyowa Kirin, INC. | $109.82 | 2023-2025 | Crysvita |
| Ascendis Pharma Endocrinology INC | $101.60 | 2023-2025 | Yorvipath |
| Insulet Corporation | $90.02 | 2022-2025 | Omnipod |
| Horizon Therapeutics Plc | $85.78 | 2022-2023 | Tepezza |
| Almatica Pharma LLC | $50.31 | 2024-2025 | Teriparatide |
| Ascensia Diabetes Care US INC. | $45.15 | 2024 | |
| Lifescan, INC. | $41.04 | 2020 | |
| Rgh Enterprises LLC | $40.91 | 2023-2024 | |
| Becton, Dickinson and Company | $38.55 | 2020 | |
| Sequel Med Tech, LLC | $38.11 | 2025 | Twiist |
| Janssen Pharmaceuticals, INC | $29.56 | 2020 | |
| Nevro Corp. | $29.31 | 2022 | |
| Currax Pharmaceuticals LLC | $28.95 | 2023 | Contrave, Nexlizet, Nexletol |
| Bigfoot Biomedical INC | $27.69 | 2022 | |
| Amryt Pharma Holdings LTD | $24.18 | 2023 | Mycapssa |
| Eusa Pharma (US) LLC | $20.99 | 2022 | |
| Amarin Pharma, INC. | $20.76 | 2020 | |
| Cequr Corporation | $20.37 | 2022 | |
| Companion Medical, INC. | $17.99 | 2020 | |
| Acella Pharmaceuticals, LLC | $17.41 | 2025 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Hamraz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.